Ä¢¹½Ö±²¥

‘Three parent’ technique must not be marketed in US, says FDA

The US Food and Drug Administration has asked John Zhang, who pioneered a technique to prevent mitochondrial disease, to stop performing the procedure

petri dish
Barry Lewis/Corbis Documentary/Getty

THE “three-parent baby� technique offered by a New York fertility clinic should no longer be marketed, says the US Food and Drug Administration.

Last year, New Ä¢¹½Ö±²¥ revealed that John Zhang of the New Hope Fertility Center had used his own mitochondrial replacement technique to create an embryo from a couple’s egg and sperm, plus mitochondrial DNA from another woman. This meant the couple didn’t pass on a fatal genetic mitochondrial disorder to the resulting child.

Because the FDA had denied Zhang’s application for a licence to perform this procedure in people, the embryo was created in the US, but implanted into the mother’s uterus in Mexico. Now Mary Malarkey of the FDA has , saying that “such human subject research cannot legally be performed in the United States�.

The websites of Zhang’s clinic and his biotech company Darwin Life promote the procedure as “the first proven treatment for certain genetic disorders� and “a cure for mitochondrial disease�. But mitochondrial replacement therapies cannot be marketed without a valid licence, says the FDA.

This article appeared in print under the headline “3-parent warning�

Topics: Biology / Diseases / Embryology / Fertility / Genetics